MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer
Stopped early · Phase 1
Conditions studied: Brain and Central Nervous System Tumors
In brief
RATIONALE: MK0752 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of MK0752 in treating young patients with recurrent or refractory CNS cancer.
Key facts
- Study ID
- NCT00572182
- Run by
- Pediatric Brain Tumor Consortium
- People needed
- 33
- Starts
- 2008-07-01
- Expected to finish
- 2011-02-01
- Last updated by the study team
- 2012-03-06
Who can join
Age: 3 and older, up to 21. Sex: any. Healthy volunteers: not accepted.
Where it is running
- UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California, United States
- Children's National Medical Center — Washington D.C., District of Columbia, United States
- Children's Memorial Hospital - Chicago — Chicago, Illinois, United States
- NCI - Pediatric Oncology Branch — Bethesda, Maryland, United States
- Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute — Boston, Massachusetts, United States
- Duke Comprehensive Cancer Center — Durham, North Carolina, United States
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio, United States
- Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States
- Children's Hospital of Pittsburgh — Pittsburgh, Pennsylvania, United States
- St. Jude Children's Research Hospital — Memphis, Tennessee, United States
- Dan L. Duncan Cancer Center at Baylor College of Medicine — Houston, Texas, United States
- Seattle Children's Hospital — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.